Elecsys® BRAHMS Procalcitonin (PCT)

Fully automated, reliable, realtime clinical decision support for the management of sepsis

Elecsys® BRAHMS Procalcitonin (PCT)

Elecsys® BRAHMS Procalcitonin (PCT) delivers fully automated, reliable, realtime clinical decision support for the management of sepsis.

Elecsys BRAHMS PCT helps personalise your sepsis patient management by providing reliable real-time clinical decision support data about the source of a suspected infection, disease severity & progression, and response to treatment.

PCT levels increase as sepsis progresses and severity increases, allowing the differentiation of patients with SIRS, sepsis, severe sepsis or septic shock. PCT is a biomarker with high specificity for an inflammatory response to a bacterial infection. PCT concentrations in the blood can aid clinicians in the detection of clinically relevant bacterial infections. PCT is considered a prognostic marker to support outcome prediction in sepsis patients. PCT can be used for decision of antibiotic treatment necessity and to monitor treatment success in LRTI.1,2,3,4

 

About Sepsis

 

Sepsis is life threatening organ dysfunction caused by a dysregulated host response to infection.5,6,7 Sepsis and septic shock are major healthcare problems, with more than 1 in 1000 people in developed countries suffering from sepsis each year.8 Early identification and appropriate management in the initial hours after sepsis develops improves outcomes.9

 

Benefits

 

Elecsys BRAHMS PCT helps to improve your sepsis patient management by providing reliable realtime clinical decision support data about a suspected infection, disease severity, and response to treatment.

  • Low sample volume
  • Broad measuring range
  • Short total assay time
  • Excellent inter- and intra-assay CV (coefficient of variation)
  • Available on all cobas e analyzers
Elecsys BRAHMS Procalcitonin (PCT)

Elecsys® BRAHMS Procalcitonin (PCT)

  • Assay time

    18 min

  • Sample material

    Serum collected using standard sampling tubes or tubes containing separating gel. Liheparin, K3‑EDTA plasma.

  • Sample volume

    30 μL

  • Analytical Sensitivity

    <0.02 ng/mL

  • Functional Sensitivity

    <0.06 ng/mL

  • Traceabilty

    Standardized against BRAHMS PCT LIA

  • Measuring range

    0.02-100 ng/mL
    (defined by the lower detection limit and the maximum of the master curve)

References

 

  1. Clec’h C, Ferriere F, Karoubi P, et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med. 2004;32(5):11661169.
  2. Novotny A, Emmanuel K, Matevossian E, et al. Use of procalcitonin for early prediction of lethal outcome of postoperative sepsis. The American Journal of Surgery 2007;194:3539.
  3. Hausfater P, Juillien G, MadonnaPy B, et al. Serum procalcitonin measurement as diagnostic and prognostic marker in febrile adult patients presenting to the emergency department. Crit Care. 2007;11(3):6069.
  4. Dahaba AA, Hagara B, Fall A, et al. Procalcitonin for early prediction of survival outcome in postoperative critically ill patients with severe sepsis. Br J Anaesth 2006;97:503508.
  5. Singer M, Deutschman CS, Seymour CW et al (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis3). JAMA 315(8):801–810
  6. ShankarHari M, Phillips GS, Levy ML et al (2016) Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis3). JAMA 315(8):775–787
  7. Seymour CW, Liu VX, Iwashyna TJ et al (2016) Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis3). JAMA 315(8):762–774
  8. Issrah Jawad, et al: "Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality." J Glob Health. 2012 Jun; 2(1): 00404
  9. Rhodes Andrew et al (2016) Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med DOI 10.1007/s0013401746836